Jallal To Lead Immunocore, Building On Partnership She Forged At MedImmune
Executive Summary
A key figure in AstraZeneca’s resurgence, Jallal now leaves to head up a clinical-stage firm. She’s been an outspoken advocate for greater gender equity in biopharma leadership.
You may also be interested in...
Farewell To MedImmune: AstraZeneca Will Combine Large And Small Molecule Research
The company will integrate MedImmune, which has operated as the biologics research arm of AstraZeneca, amid an R&D and commercial restructuring.
AZ Management Shake-Up Sees CMO Bohen Exit
Sean Bohen is to join Bahija Jallal, Mark Mallon and Ludovic Helfgott in leaving AstraZeneca as the company transitions to a new organizational structure announced last week by CEO Pascal Soriot.
AstraZeneca Rejig Brings Baselga On Board
A reorganization at the top of the UK firm brings with it controversial scientist Jose Baselga.